Norbrook Laboratories Ltd v. Bomac Laboratories Ltd (New Zealand)

Link copied
Case Copied 22 min read

    Norbrook Laboratories Ltd v. Bomac Laboratories Ltd (New Zealand ) [2006] UKPC 25 (4 May 2006)

    Privy Council Appeal No 41 of 2005
    Norbrook Laboratories Limited Appellant
    v.
    Bomac Laboratories Limited Respondent
    FROM
    THE COURT OF APPEAL OF
    NEW ZEALAND
    - - - - - - - - - - - - - - - - -
    JUDGMENT OF THE LORDS OF THE JUDICIAL
    COMMITTEE OF THE PRIVY COUNCIL
    Delivered the 4th May 2006
    - - - - - - - - - - - - - - - - -
    Present at the hearing:-

    Lord Bingham of Cornhill

    Lord Hope of Craighead

    Lord Carswell

    Lord Mance

    Sir Martin Nourse

    - - - - - - - - - - - - - - - -

    [Delivered by Lord Bingham of Cornhill]

  1. The issue in this appeal is whether the Court of Appeal of New Zealand was wrong to conclude that the respondent had not breached its contractual undertaking to the appellant to "maintain in confidence and not use" confidential proprietary information communicated to it by the appellant.
  2. The agreed facts
  3. Most of the facts central to the dispute between the parties have helpfully been agreed between them.
  4. The appellant, Norbrook Laboratories Limited, is a company registered in Northern Ireland. It develops, manufactures and sells veterinary pharmaceutical products. In the late 1970s it developed an antibiotic intramammary dry cow remedy which it marketed as Bovaclox DC. It later developed a longer acting variant of Bovaclox DC which it marketed as Bovaclox DC Xtra. The only significant difference between the formulations for these two products is that in Bovaclox DC Xtra, but not in Bovaclox DC, the cloxacillin ingredient is coated with a prescribed percentage of lecithin, a complex chemical compound. This prescribed percentage was, and remains, confidential, and the issue in this appeal relates to it. To avoid disclosure of this figure, the Board will refer to it as "x%".
  5. The respondent, Bomac Laboratories Limited, is a New Zealand company that develops, manufactures, markets and distributes animal health and nutritional products for sale in New Zealand and other countries. From 1984 to June 2001 Norbrook sold various veterinary pharmaceutical products to Bomac, which Bomac sold in New Zealand. One of these products was Bovaclox DC, which Bomac marketed from 1986 onwards under its own trade name, Dryclox DC. To do this, Bomac required a licence from the regulatory authority in New Zealand, then the Animal Remedies Board ("the ARB"), whose functions were discharged from July 2001 by the Agricultural Compounds and Veterinary Medicines Group of the New Zealand Food Safety Authority ("the ACVM"). To enable Bomac to obtain such a licence Norbrook sent Bomac a dossier in 1984 containing extensive information, some of it confidential, about Bovaclox DC.
  6. In April 1988 Norbrook and Bomac made a written Secrecy Agreement. By clause 3 of this agreement Bomac undertook that for a period of 15 years from the date of receipt it would "maintain in confidence and not use, except as…
CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Norbrook Laboratories Ltd v. Bomac Laboratories Ltd (New Zea... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2006] UKPC 25
Decision Date

CaseChat Overview and Summary

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established